Search alternatives:
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
largest decrease » largest decreases (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
481
-
482
-
483
-
484
-
485
-
486
mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes.
Published 2020“…<p>(<b>A</b>) Primary cultured podocytes were isolated from <i>Tsc2</i><sup>Δ<i>podocyte</i></sup> and wild-type controls, followed by western blot analyses of TSC2, phospho-4EBP1, LC3B type II, p62, phospho-ULK1, and β-tubulin. …”
-
487
-
488
-
489
-
490
-
491
(+)-Usnic acid decreases β-catenin-mediated TOPFLASH activity and KITENIN-mediated AP-1 activity.
Published 2016“…<p>(A) β-Catenin-mediated transcriptional activity of TOPFLASH promoter was decreased by (+)-usnic acid treatment. …”
-
492
Decreased α-cell mass and early structural alterations of the exocrine pancreas in patients with type 1 diabetes: An analysis based on the nPOD repository
Published 2018“…Results were expressed as mean ±SD.</p><p>Results</p><p>An automated quantification method was set up using the R software and was validated by quantification of β-cell mass, a well characterized parameter. β-cell mass was 29.6±112 mg in patients and 628 ±717 mg in controls (p<0.0001). α-cell mass was 181±176 mg in patients and 349 ±241mg in controls (p<0.0001). …”
-
493
-
494
-
495
-
496
-
497
-
498
-
499
<i>TERT-CLPTM1L</i> Rs401681 C>T Polymorphism Was Associated with a Decreased Risk of Esophageal Cancer in a Chinese Population
Published 2014“…</p><p>Results</p><p>When the <i>TERT-CLPTM1L</i> rs401681 CC homozygote genotype was used as the reference group, the CT genotype was associated with a significantly decreased risk of ESCC (adjusted OR = 0.74, 95% CI = 0.58–0.94, <i>p</i> = 0.012); the CT/TT variants were associated with a 26% decreased risk of ESCC (adjusted OR = 0.74, 95% CI = 0.59–0.93, <i>P</i> = 0.009). …”
-
500